You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said it intends to use the technology to develop infectious disease diagnostics, with an initial focus on SARS-CoV-2.
Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management.
Rhinostics said it plans to purse Emergency Use Authorization from the FDA for the swab for home collection with PCR testing.
Of the 32 companies in the index, 21 firms saw their stock prices increase, while 11 firms' share prices decreased.
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
The deal complements rights Sherlock already holds from the Broad Institute, which developed Sherlock's platform.
TwinStrand's duplex sequencing correction technology can detect ultra-low frequency DNA mutations that are otherwise often obscured by technical noise.
The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.
The firm signed a deal with Zotal to be exclusive Israeli distributor of the test, which measures proteins in patient blood to detect diabetic kidney disease.